U.S. markets closed

ProKidney Corp. (PROK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6850+0.0050 (+0.30%)
At close: 04:00PM EST
1.7300 +0.05 (+2.67%)
After hours: 06:02PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.6800
Bid1.6300 x 1300
Ask1.7800 x 1300
Day's Range1.6000 - 1.7300
52 Week Range1.1200 - 14.1900
Avg. Volume1,026,801
Market Cap1.812B
Beta (5Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-0.5800
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PROK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ProKidney Corp.
    PRVA: What does Argus have to say about PRVA?PRIVIA HEALTH GROUP INC has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer

    Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidneyWINSTON-SALEM, N.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Nikhil Pereira-Kamath, MBA, Vice President of Business Development & Innovative Solutions, to Chief Business Officer (CBO). As CBO, Nikhil will have global respon

  • InvestorPlace

    7 Penny Stocks With Low Floats and High Short Interest

    There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short. With the short side of the trade heavily crowded, and a few shares publicly available to cover these short positions, there is the potential for big gains for those on the long side of the trade. A sudd

  • GlobeNewswire

    ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference

    WINSTON-SALEM, N.C, Nov. 21, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients living with chronic kidney disease (CKD), today announced that management will be participating in a fireside chat at the 6th Annual Evercore ISI HEALTHCONx Conference being held in Miami, Florida on November 28-30, 2023. Evercore ISI HEALTHCONx Conference Date: Thursday,